Publications by authors named "P Grivas"

Claim this Profile
E
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.
Tanya Jindal, Cindy Y Jiang, Omar Alhalabi, Matthew Davidsohn, Dory Freeman, Petros Grivas

Urol Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study.
B A Maiorano, A Cigliola, V Tateo, C Mercinelli, G L Pastorino, P Grivas

ESMO Open· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract.
Thomas Powles, Scott T Tagawa, Christof Vulsteke, Marine Gross-Goupil, Se Hoon Park, Petros Grivas

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
Rana R McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges, Petros Grivas

CA Cancer J Clin· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Cindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, Dimitra Rafailia Bakaloudi, Rafee Talukder, Petros Grivas

Oncologist· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis